São Paulo, November 18, 2021 – Eurofarma, a multinational corporation with own operations across 20 Latin American countries, has signed an agreement to purchase Hypera Pharma assets, recently acquired from Sanofi for the Mexican and Colombian markets. 

The purchase includes Calcigenol (calcium) and Melox (antacid) in Mexico; Pepsamar (antacid) and Pax (flu medication) in Colombia. The annual revenues for the products add up to approximately USD 15 million. With these new assets, the company expects to climb from the 33rd to 26th position in the ranking of the largest pharmaceutical companies in Colombia, and from the 43rd to 38th position in the ranking of the largest pharmaceutical companies in Mexico. 

The company adds this acquisition to others made recently in both countries. In 2021, Eurofarma completed the purchase of 12 drugs from Takeda, 1 product from Lilly in Mexico and 6 products from Grünenthal in Colombia. The decision is in line with the company’s strategic plan and with the goal of international revenues representing 30% of the company’s total by 2022. With an average growth rate of 17% in the last 10 years, Eurofarma occupies a prominent position in Brazil, being the leading corporation in Prescription Drugs and vice-leader in Generic Drugs.